COVID-19
Conditions
Interventions
None listed
Sponsors
Nara Medical University Center for Infectious Diseases
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients suspected to have COVID-19 and underwent SARS-CoV2 PCR test during the study period (after Ethics Committee approval - March 31, 2022) Selection Criteria 1. patients with pneumonia requiring hospitalization who need to be differentiated from COVID-19 Patients who have been in contact with a confirmed COVID-19 patient or have traveled to an endemic area within 14 days of onset and require hospitalization. 2. Patients with fever of 37.5 degree or higher and symptoms such as cough, sputum, sore throat, chest pain, dyspnea, malaise, arthralgia, myalgia, anorexia, and diarrhea 3. Acute onset taste or smell disorder Definition of endemic areas: Areas with COVID-19 infections of 0.3/100,000 population or more in the last week. 4. 4. patients aged 20 years or older at the time of nasopharyngeal swab specimen collection
Exclusion criteria
Exclusion criteria: 1. If the participant is judged to be ineligible for research. 2. those who refuse to participate in the research
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FilmArray Respiratory Panel 2.1 Test Results (including SARS-CoV2) | — |
Secondary
| Measure | Time frame |
|---|---|
| Presence of other microbial infections in SARS-CoV-2 PCR-positive patients SARS-CoV-2 PCR results by GeneSoC. Test results of FilmArray Respiratory Panel 2.1 compared to SARS-CoV-2 PCR Sensitivity, Specificity and Minimum Detection Sensitivity of SARS-CoV-2 Antibody Test Reagent Kits (IgM, IgG) and COVID-19 IgG/IgM Immunochromatographic Kit | — |
Countries
Japan
Contacts
Public ContactTatsuya Fukumori
Nara Medical University Center for Infectious Diseases
Outcome results
None listed